157 related articles for article (PubMed ID: 38104861)
1. Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury.
Lu Q; Zhu Y; Wang C; Zhang R; Miao Y; Chai Y; Jiang Z; Yu Q
Life Sci; 2024 Jan; 337():122355. PubMed ID: 38104861
[TBL] [Abstract][Full Text] [Related]
2. Lignans from Schisandra sphenanthera protect against lithocholic acid-induced cholestasis by pregnane X receptor activation in mice.
Fan S; Liu C; Jiang Y; Gao Y; Chen Y; Fu K; Yao X; Huang M; Bi H
J Ethnopharmacol; 2019 Dec; 245():112103. PubMed ID: 31336134
[TBL] [Abstract][Full Text] [Related]
3. Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis.
Liu J; Liu J; Meng C; Huang C; Liu F; Xia C
Phytomedicine; 2022 Jul; 102():154173. PubMed ID: 35605478
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway.
Song G; Weng F; Zou B; Zhao J; Jin J; Yan D; Huang K; Sun X; Liu C; Hu Y; Li Y; Qiu F
Clin Sci (Lond); 2023 Apr; 137(7):561-577. PubMed ID: 36795945
[TBL] [Abstract][Full Text] [Related]
5. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
6. The choleretic role of tauroursodeoxycholic acid exacerbates alpha-naphthylisothiocyanate induced cholestatic liver injury through the FXR/BSEP pathway.
Zhao J; Song G; Weng F; Li Y; Zou B; Jin J; Yan D; Sun X; Liu C; Qiu FR
J Appl Toxicol; 2023 Jul; 43(7):1095-1103. PubMed ID: 36787806
[TBL] [Abstract][Full Text] [Related]
7. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
[TBL] [Abstract][Full Text] [Related]
8. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
9. Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury.
Gao X; Fu T; Wang C; Ning C; Kong Y; Liu Z; Sun H; Ma X; Liu K; Meng Q
Biochem Pharmacol; 2017 Dec; 146():127-138. PubMed ID: 28987596
[TBL] [Abstract][Full Text] [Related]
10. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
12. Da-Huang-Xiao-Shi decoction protects against3, 5-diethoxycarbonyl-1,4-dihydroxychollidine-induced chronic cholestasis by upregulating bile acid metabolic enzymes and efflux transporters.
Xue H; Fang S; Zheng M; Wu J; Li H; Zhang M; Li Y; Wang T; Shi R; Ma Y
J Ethnopharmacol; 2021 Apr; 269():113706. PubMed ID: 33346024
[TBL] [Abstract][Full Text] [Related]
13. The Function of Multidrug Resistance-associated Protein 3 in the Transport of Bile Acids under Normal Physiological and Lithocholic Acid-induced Cholestasis Conditions.
Wang W; Zeng S; Hu M; Liu Z; Gong L
Curr Drug Metab; 2021; 22(5):353-362. PubMed ID: 33461458
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity.
Kong Y; Gao X; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Sun P; Meng Q
Eur J Pharmacol; 2018 Apr; 824():64-71. PubMed ID: 29427579
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor contributes to oleanolic acid-induced cholestatic liver injury in mice.
Feng H; Hu Y; Zhou S; Lu Y
J Appl Toxicol; 2022 Aug; 42(8):1323-1336. PubMed ID: 35128688
[TBL] [Abstract][Full Text] [Related]
16. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
17. Effects of Yinzhihuang on Alleviating Cyclosporine A-Induced Cholestatic Liver Injury via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Vitro and in Vivo.
Qin Y; Tan J; Han X; Wang N; Zhai X; Lu Y
Biol Pharm Bull; 2023; 46(12):1810-1819. PubMed ID: 38044100
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
19. Identifying hepatoprotective mechanism and effective components of Yinchenzhufu decoction in chronic cholestatic liver injury using a comprehensive strategy based on metabolomics, molecular biology, pharmacokinetics, and cytology.
Li Y; Peng X; Wang G; Zan B; Wang Y; Zou J; Tian T; Meng Q; Shi R; Wang T; Wu J; Ma Y
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117060. PubMed ID: 37598769
[TBL] [Abstract][Full Text] [Related]
20. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.
Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q
Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
